PMID- 33964809
OWN - NLM
STAT- MEDLINE
DCOM- 20220107
LR  - 20220107
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 97
DP  - 2021 Aug
TI  - APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal 
      squamous cell carcinoma.
PG  - 107675
LID - S1567-5769(21)00311-8 [pii]
LID - 10.1016/j.intimp.2021.107675 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) and hypopharyngeal squamous cell 
      carcinoma (HSCC) seriously affect the life quality of patients. Nowadays, 
      immunotherapy is widely used in the treatment of cancer. Tumor-infiltrating 
      lymphocytes (TILs), programmed cell death 1 (PD-1) and its ligand programmed cell 
      death ligand 1 (PD-L1) play key roles in the immunotherapy of cancer. Moreover, 
      study has reported that the upregulation of PD-L1 and apurinic/apyrimidinic 
      endonuclase 1 (APE1) are associated with tumorigenesis and poor prognosis of 
      gastric cancer. In the present study, the number of CD3+ T lymphocytes and the 
      expressions of PD-1 and PD-L1 in LSCC and HSCC were detected in clinical samples. 
      In addition, the expressions of PD-L1 and APE1 and their correlation were 
      explored. The results showed that PD-1+ T lymphocytes were wildly infiltrated and 
      PD-L1 was overexpressed in LSCC and HSCC tissues. PD-1 had a positive correlation 
      with cancer progression, and glottic and subglottic LSCC tissues might have a 
      more active immune microenvironment. Moreover, the results showed that 
      upregulated co-expression of PD-L1 and APE1 was a biomarker of LSCC, and APE1 
      could regulate the expression of PD-L1 through NF-kappaB signaling pathway. In 
      conclusion, the combine detection of the expressions of PD-1, PD-L1 and APE1 will 
      provide predictive value for the treatment of LSCC and HSCC via immune checkpoint 
      inhibitors, which will help us to identify the patient population more likely to 
      benefit from the immune checkpoint inhibitors based on the tumor immune 
      microenvironment.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Wang, Juan
AU  - Wang J
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao 266061, Shandong, China.
FAU - Lun, Limin
AU  - Lun L
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao 266061, Shandong, China.
FAU - Jiang, Xin
AU  - Jiang X
AD  - Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China 
      Medical University, Shenyang 110004, Liaoning, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao 266061, Shandong, China.
FAU - Li, Xiaopeng
AU  - Li X
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao 266061, Shandong, China.
FAU - Du, Guoqiang
AU  - Du G
AD  - Department of Otolaryngology Head and Neck Surgery, Qingdao Municipal Hospital 
      (Group), Qingdao 266071, Shandong, China. Electronic address: dugq2020@163.com.
FAU - Wang, Jin
AU  - Wang J
AD  - Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China 
      Medical University, Shenyang 110004, Liaoning, China. Electronic address: 
      wangj10@sj-hospital.org.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210506
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (NF-kappa B)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - EC 4.2.99.18 (APEX1 protein, human)
RN  - EC 4.2.99.18 (DNA-(Apurinic or Apyrimidinic Site) Lyase)
SB  - IM
MH  - B7-H1 Antigen/antagonists & inhibitors/*genetics/metabolism
MH  - Biomarkers, Tumor/antagonists & inhibitors/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Chemotherapy, Adjuvant/methods
MH  - DNA-(Apurinic or Apyrimidinic Site) Lyase/*metabolism
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects/immunology
MH  - Humans
MH  - Hypopharyngeal Neoplasms/diagnosis/genetics/*immunology/therapy
MH  - Immune Checkpoint Inhibitors/pharmacology/therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/diagnosis/genetics/*immunology/therapy
MH  - Male
MH  - Middle Aged
MH  - NF-kappa B/metabolism
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/metabolism
MH  - Signal Transduction/genetics/immunology
MH  - Squamous Cell Carcinoma of Head and Neck/diagnosis/genetics/*immunology/therapy
MH  - Tumor Microenvironment/drug effects/genetics/immunology
MH  - Up-Regulation/drug effects/immunology
OTO - NOTNLM
OT  - APE1
OT  - Hypopharyngeal squamous cell carcinoma
OT  - Laryngeal squamous cell carcinoma
OT  - PD-1
OT  - PD-L1
OT  - TILs
EDAT- 2021/05/09 06:00
MHDA- 2022/01/08 06:00
CRDT- 2021/05/08 20:27
PHST- 2021/01/31 00:00 [received]
PHST- 2021/03/18 00:00 [revised]
PHST- 2021/04/11 00:00 [accepted]
PHST- 2021/05/09 06:00 [pubmed]
PHST- 2022/01/08 06:00 [medline]
PHST- 2021/05/08 20:27 [entrez]
AID - S1567-5769(21)00311-8 [pii]
AID - 10.1016/j.intimp.2021.107675 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Aug;97:107675. doi: 10.1016/j.intimp.2021.107675. Epub 
      2021 May 6.